Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan.
Dirk Jan A R MoesJeroen J M A HendrikxHenk-Jan GuchelaarRon H J MathijssenJ L BakkerVincent O DezentjéNikki de RouwNielka P van ErpEgbert F SmitMichel van den HeuvelThijs H Oude MunninkMaartje van KatsSander CroesJudith R KroepJuliette ZwavelingRob Ter HeinePublished in: Targeted oncology (2024)
With the alternative dosing proposal, an approximately 20% reduction in drug expenses for sacituzumab govitecan can be realized while maintaining an equivalent and more evenly distributed exposure throughout the body weight range, without notable increases in pharmacokinetic variability.
Keyphrases